Cited 25 times in
Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박용범 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 송정식 | - |
dc.contributor.author | 안성수 | - |
dc.contributor.author | 이상원 | - |
dc.contributor.author | 정승민 | - |
dc.date.accessioned | 2018-08-28T17:03:22Z | - |
dc.date.available | 2018-08-28T17:03:22Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/162210 | - |
dc.description.abstract | To investigate whether the use of IL-6 receptor antagonist (tocilizumab) might be associated with hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) patients, particularly in those with resolved HBV infection [HBV surface antigen (HBsAg) negative and antibody to HBV core antigen (anti-HBc) positive, serologically]. HBsAg, anti-HBc, antibody to HBsAg (anti-HBs), and HBV DNA titers were measured in RA patients who had continuously received tocilizumab for more than 3 months. Patients were divided into two groups according to the presence of anti-HBc. Clinical and laboratory data, in addition to medications administered along with tocilizumab during the treatment duration with tocilizumab, were compared between the two groups. HBV reactivation was defined as the presence of HBV DNA in sera, and alterations in HBsAg, anti-HBc, and anti-HBs titers according to the use of tocilizumab were also evaluated. Fifteen of 39 patients (38.5%) had anti-HBc positivity, while 24 patients (61.5%) did not. There were no differences in demographic data, serologic classification, and variables related to tocilizumab between the anti-HBc-positive and -negative groups. Comparison of the medications administered along with tocilizumab treatment revealed no meaningful differences. None of the patients experienced reactivation of HBV. In addition, in 15 patients with resolved HBV infection, no alterations in HBsAg, anti-HBc, and anti-HBs titers were observed with the use of tocilizumab. Tocilizumab may be applied to RA patients safely with few concerns for HBV reactivation, particularly in those with resolved HBV infection. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Monoclonal Antibodies, Humanized/*adverse effects/therapeutic use | - |
dc.subject.MESH | Antirheumatic Agents/*adverse effects/therapeutic use | - |
dc.subject.MESH | Rheumatoid/diagnosis/*drug therapy/immunology Arthritis | - |
dc.subject.MESH | Viral DNA | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hepatitis B/immunology/prevention & control/*virology | - |
dc.subject.MESH | Hepatitis B Antibodies/blood | - |
dc.subject.MESH | Hepatitis B Surface Antigens/blood | - |
dc.subject.MESH | Hepatitis B virus/genetics/immunology/*physiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunocompromised Host | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Real-Time Polymerase Chain Reaction | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Virus Activation/immunology/*physiology | - |
dc.title | Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Sung Soo Ahn | - |
dc.contributor.googleauthor | Seung Min Jung | - |
dc.contributor.googleauthor | Jason Jungsik Song | - |
dc.contributor.googleauthor | Yong Beom Park | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Sang Won Lee | - |
dc.identifier.doi | 10.3349/ymj.2018.59.3.452 | - |
dc.contributor.localId | A01579 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02057 | - |
dc.contributor.localId | A02233 | - |
dc.contributor.localId | A02824 | - |
dc.contributor.localId | A05179 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 29611409 | - |
dc.subject.keyword | Tocilizumab | - |
dc.subject.keyword | hepatitis B | - |
dc.subject.keyword | reactivation | - |
dc.subject.keyword | rheumatoid arthritis | - |
dc.contributor.alternativeName | Park, Yong Beom | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Song, Jung Sik | - |
dc.contributor.alternativeName | Ahn, Sung Soo | - |
dc.contributor.alternativeName | Lee, Sang Won | - |
dc.contributor.alternativeName | Jung, SeungMin | - |
dc.contributor.affiliatedAuthor | Park, Yong Beom | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Song, Jung Sik | - |
dc.contributor.affiliatedAuthor | Ahn, Sung Soo | - |
dc.contributor.affiliatedAuthor | Lee, Sang Won | - |
dc.contributor.affiliatedAuthor | Jung, SeungMin | - |
dc.citation.volume | 59 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 452 | - |
dc.citation.endPage | 456 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.59(3) : 452-456, 2018 | - |
dc.identifier.rimsid | 59796 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.